Drugs / CEL383
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05901883 | Jun 2023 → Jan 2024 | — | Celsius Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEL383 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05901883 ↗ |
| Route | Intravenous | “When Administered Intravenously” NCT05901883 ↗ |